Creatine transporter deficiency syndrome 1 (CCDS1), also known as creatine transporter deficiency, is an inherited disorder of creatine metabolism caused by variants in the SLC6A8 gene. It is inherited in an X-linked manner and primarily affects males, in whom the transporter alteration prevents the adequate entry of creatine into the brain and causes intellectual disability, speech delay, and other neurological symptoms.
Cerebral creatine deficiency syndrome 1 (SLC6A8)
The SLC6A8 gene (Solute Carrier Family 6 Member A8) is located on the X chromosome and encodes the creatine transporter 1 (CRTR/CreaT), a membrane protein that allows creatine to enter cells. Creatine participates in the creatine-phosphocreatine system, which acts as a rapid energy reserve for tissues with high metabolic demand, especially the brain and muscle. Pathogenic variants in SLC6A8 reduce or abolish transporter function, leading to insufficient creatine uptake by the brain, even when it is available in the blood. This results in a cerebral creatine depletion, detectable by magnetic resonance spectroscopy, and an alteration of neuronal energy metabolism. Inheritance is X-linked: hemizygous males typically present with the full phenotype, whereas heterozygous females may be asymptomatic or show a variable degree of intellectual disability, learning difficulties, seizures, or behavioral symptoms due to X chromosome inactivation. It is a rare disease and a recognized cause of X-linked intellectual disability; many cases appear de novo or due to maternal mosaicism.
Symptoms
The onset is often evident in early childhood, with global developmental delay and speech delay, especially expressive language. Affected males may present moderate to severe intellectual disability, hypotonia, epilepsy with different seizure types, behavioral disorders, autistic features, hyperactivity, impulsivity, or social anxiety. Feeding problems or low weight, constipation, movement disorders, and less frequently, cardiac abnormalities such as QTc interval prolongation have also been described. In heterozygous females, the clinical expression is highly variable and can be mild.
Disease management
Management is multidisciplinary and focuses on neurological, behavioral, educational, and rehabilitative support. Supplementation with creatine, L-arginine, and glycine may be used, but the response is often limited in SLC6A8 deficiency because the primary defect affects creatine transport into the brain; its efficacy should be evaluated individually. Seizures, movement disorders, and behavioral problems are treated with standard measures from each specialty. Neurological, developmental, and renal function monitoring is recommended if creatine is used, along with family genetic counseling to identify carrier females and assess reproductive risk.
Genes analyzed
Bibliography
Goldstein J, Thomas-Wilson A, Groopman E, et al. ClinGen variant curation expert panel recommendations for classification of variants in GAMT, GATM and SLC6A8 for cerebral creatine deficiency syndromes. Mol Genet Metab. 2024 May;142(1):108362.
Passi GR, Pandey S, Devi ARR, et al. Cerebral creatine deficiency disorders - A clinical, genetic and follow up study from India. Brain Dev. 2022 Apr;44(4):271-280.
Longo N, Voss LA, Frigeni M, et al. Response to therapy of creatine transporter deficiency caused by a hypomorphic variant in SLC6A8. Mol Genet Metab. 2024 Nov;143(3):108595.
Ito S, Uemura T, Miyano A, et al. Effects of SLC6A8 mutation-induced creatine deficiency on cellular function in fibroblasts. Sci Rep. 2025 Jul 23;15(1):26738.
Gechijian LN, Muncipinto G, Rettenmaier TJ, et al. Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency. ACS Chem Biol. 2024 Nov 15;19(11):2372-2382.
